thiotepa has been researched along with Stroke in 2 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJ | 2 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 2 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 2 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 2 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Dell'Oro, S | 1 |
| Foppoli, M | 1 |
| Bernardi, M | 1 |
| Brandes, AA | 1 |
| Tosoni, A | 1 |
| Montanari, M | 1 |
| Spina, M | 1 |
| Ilariucci, F | 1 |
| Zaja, F | 1 |
| Stelitano, C | 1 |
| Bobbio, F | 1 |
| Corazzelli, G | 1 |
| Baldini, L | 1 |
| Picozzi, P | 1 |
| Caligaris Cappio, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thiotepa and Stroke
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2006 |